OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Clinical trials for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat ovarian cancer: drug combo shows promise
Disease control OngoingThis study tests whether adding a drug called AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has returned and is resistant to platinum-based treatments. About 124 women will be randomly assigned to receive either…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:07 UTC
-
Drug cocktail shows promise for Tough-to-Treat ovarian and breast cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:06 UTC